K2 Principal Fund’s Translational Development Acquisition Corp Warrants TDACW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$145K Sell
100,113
-921
-0.9% -$1.59K 0.01% 319
2026
Q2
$143K Sell
101,034
-95,425
-49% -$95.8K 0.01% 358
2026
Q1
$23.6K Sell
196,459
-49,230
-20% -$11.3K ﹤0.01% 434
2025
Q4
$76.2K Sell
245,689
-50,000
-17% -$16.4K 0.01% 337
2025
Q3
$85.8K Hold
295,689
– – 0.01% 279
2025
Q2
$68K Hold
295,689
– – 0.01% 244
2025
Q1
$41.4K Buy
+295,689
New +$52K 0.01% 278

Other funds holding TDACW

K2 Principal Fund's TDACW Position: Q3 2026 in Review

K2 Principal Fund reduced its Translational Development Acquisition Corp Warrants (TDACW) stake by 0.91% in Q3 2026, selling an estimated $1.59K and leaving 100,113 shares worth $145K. The position accounts for 0.01% of the portfolio, ranked #319.

K2 Principal Fund first reported a position in TDACW in Q1 2025 and has held it in 7 quarters since. 17 funds tracked by Wall St. Rank hold TDACW as of Q3 2026.

  • K2 Principal Fund held 100,113 shares of Translational Development Acquisition Corp Warrants worth $145K as of Q3 2026.
  • K2 Principal Fund sold 921 Translational Development Acquisition Corp Warrants shares in Q3 2026, an estimated $1.59K.
  • Translational Development Acquisition Corp Warrants made up 0.01% of K2 Principal Fund's portfolio in Q3 2026, its #319 holding.
  • K2 Principal Fund first reported a position in Translational Development Acquisition Corp Warrants in Q1 2025 and has held it in 7 quarters since.
  • 17 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Warrants as of Q3 2026.

Based on K2 Principal Fund's 13F filing for Q3 2026, filed 13 Nov 2026.